Dual time point positron emission tomography/computed tomography scan in evaluation of intrathoracic lesions in an area endemic for histoplasmosis and with high prevalence of sarcoidosis

American Journal of the Medical Sciences

Volumn 346, Issue 5, 2013, Pages 358-362

  Kadaria, Dipen ^a   Archie, David S ^b   Sultanali, Ibrahim ^b   Weiman, Darryl S ^b   Freire, Amado X ^a   Zaman, Muhammad K ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Histoplasmosis; Intrathoracic lymphadenopathy; PET scan

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BENIGN TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPLASMOSIS; HUMAN; LUNG NODULE; LUNG TUMOR; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NEOPLASM; PREDICTIVE VALUE; PREVALENCE; SARCOIDOSIS;

EID: 84887242481     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31827b9b6d     Document Type: Article

References (23)

1. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
2. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules: potential role in evaluation and management. Chest 1993;104:997-1002.
3. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET. Chest 1996;109:982-8.
4. Schillaci O, Travascio L, Bolacchi F, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 2009;114: 890-906. Epub ahead of print 2009 Jul 4.
5. Matthies A, Hickeson M, Cuchiara A, et al. Dual time point 18FFDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43:871-5.
6. Byrant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 2006;82:1016-20.
7. Patz EF, Lowe VJ, Hoffinan JM, et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90.
8. Croft DR, Trapp J, Kernstine K, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002;36:297-301.
9. Salhab KF, Baram D, Bilfinger TV. Growing PET positive nodule in a patient with histoplasmosis: case rep. J Cardiothorac Surg 2006;1:23.
10. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345-8.
11. Núñez R, Kalapparambath A, Varela J. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET. Rev Esp Med Nucl 2007;26:196-207.
12. Hu M, Han A, Xing L, et al. Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med 2011;36:429-33.
13. Suga K, Kawarkami Y, Hiyama A, et al. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan. Ann Nucl Med 2009;23:523-31.
14. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumor detection. Eur J NuclMed 2001;28:696-703.
15. Chen CJ, Lee BF, Yao WJ, et al. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol 2008;191:475-9.
16. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7.
17. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551-5.
18. Xiu Y, Bhutani C, Dhurairaj T, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007;32:101-5.
19. Sahlmann CO, Siefker U, Lehmann K, et al. Dual time point 2-[18F] fluoro-2-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun 2004;25:819-23.
20. Uesaka D, Demura Y, Ishizaki T, et al. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. J Nucl Med 2008;49:1606-12.
21. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540-8.
22. Umeda Y, Demura Y, Morikawa M, et al. Prognostic value of dualtime- point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology 2011;16:713-20.
23. Sathekge MM, Maes A, Pottel H, et al. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J 2010;100:598-601.